Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence
- PMID: 27247629
- PMCID: PMC4872191
- DOI: 10.1177/1756287216637569
Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence
Abstract
Objectives: Peyronie's disease (PD) is a connective tissue disorder resulting in the abnormal accumulation of scar or plaques in the tunica albuginea of the penis. The condition is characterized by two phases: an active, inflammatory phase, and a stable, chronic phase. Collagenase Clostridium histolyticum (CCH) was isolated in the mid-1900s and postulated as a potential pharmacologic strategy for breaking down the abnormal connective tissue plaques of PD. Prior to the introduction of CCH, a wide variety of treatment modalities for PD were used in clinical practice, including oral and topical medications, intralesional injections, electromotive drug administration, extracorporeal shockwave therapy, traction, and invasive surgery, all with variable results. This review aims to examine the known data surrounding the use of intralesional CCH injections in the treatment of PD.
Methods: CCH is a recently US Food and Drug Administration approved pharmacologic treatment for PD. Clinical trials using intralesional CCH injection therapy for the treatment of PD were reviewed for clinical safety and efficacy of treatment.
Results: Studies demonstrated that CCH treatment administered in multiple cycles led to significant benefit in both the psychological and physical aspects of PD. The strongest evidence for CCH's effectiveness was revealed in large, multicenter randomized controlled trials (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I and II) in which intralesional CCH was combined with manual modeling of the penis. Although adverse events from treatment are relatively common, the majority are mild to moderate in degree, including penile pain, swelling, and bruising, which all resolve spontaneously.
Conclusion: Overall, evidence indicates that CCH is a valuable, effective, and safe minimally invasive treatment option for men with PD.
Keywords: Collagenase Clostridium histolyticum; Peyronie’s Disease Questionnaire; Peyronie’s disease; penile curvature; penile plaque.
Conflict of interest statement
Similar articles
-
Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update).Sex Med Rev. 2021 Apr;9(2):340-349. doi: 10.1016/j.sxmr.2020.01.005. Epub 2020 Mar 18. Sex Med Rev. 2021. PMID: 32199788
-
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12. J Sex Med. 2015. PMID: 25388099 Clinical Trial.
-
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.J Sex Med. 2017 Oct;14(10):1220-1225. doi: 10.1016/j.jsxm.2017.08.008. Epub 2017 Sep 2. J Sex Med. 2017. PMID: 28874331
-
Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.Sex Med Rev. 2018 Jan;6(1):143-156. doi: 10.1016/j.sxmr.2017.03.005. Epub 2017 Apr 25. Sex Med Rev. 2018. PMID: 28454897 Review.
-
Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie's Disease with Calcified Plaques.Eur Urol Focus. 2023 Jan;9(1):55-59. doi: 10.1016/j.euf.2022.09.019. Epub 2022 Oct 19. Eur Urol Focus. 2023. PMID: 36272924
Cited by
-
Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections.Curr Urol Rep. 2019 Jun 14;20(8):42. doi: 10.1007/s11934-019-0910-8. Curr Urol Rep. 2019. PMID: 31201571 Review.
References
-
- Arafa M., Eid H., El-Badry A., Ezz-Eldine K., Shamloul R. (2007) The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res 19: 213–217. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16915304 (accessed 23 October 2015). - PubMed
-
- Auxilium Pharmaceuticals Inc. (2014) Xiaflex® (Collagenase Clostridium histolyticum) [prescribing information]. 1–42.
-
- Berookhim B., Choi J., Alex B., Mulhall J. (2014) Deformity stabilization and improvement in men with untreated Peyronie’s disease. BJU Int 113: 133–136. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24053665 (accessed 23 October 2015). - PubMed
-
- Carson C., 3rd, Sadeghi-Nejad H., Tursi J., Smith T., Kaufman G., Gilbert K., et al. (2015) Analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int 116: 815–822. - PubMed
-
- Chilton C., Castle W., Westwood C., Pryor J. (1982) Factors associated in the aetiology of Peyronie’s disease. Br J Urol 54: 748–750. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources